Susanna Hallberg

Artiklar

Article: EUROPEAN JOURNAL OF NEUROLOGY. 2024;31(8):e16331
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Hallberg S; Evertsson B; Lillvall E; Boremalm M; de Flon P; Wang Y; Salzer J; Lycke J; Fink K; Frisell T; Al Nimer F; Svenningsson A
Article: LANCET NEUROLOGY. 2022;21(8):693-703
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Al Nimer F; Sundstrom P; Gunnarsson M; Johansson R; Mellergard J; Rosenstein I; Ayad A; Sjoblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J

Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:358-359
Hypogammaglobulinemia during rituximab treatment in multiple sclerosis - the Hypogamma-MS study
Hallberg S; Evertsson B; Lillvall E; Boremalm M; de Flon P; Salzer J; Lycke J; Fink K; Wang Y; Frisell T; Al Nimer F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:617-618
Prediction of gammaglobulin decrease during rituximab treatment in MS
Kallin S; Hallberg S; Evertsson B; Wang Y; Fink K; Salzer J; Lycke J; Al Nimer F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:20
Risk of hypogammaglobulinemia in long-term treatment with rituximab in multiple sclerosis
Hallberg S; Boremalm M; Evertsson B; Lillvall E; Johansson F; Lycke J; Piehl F; Salzer J; Svenningsson A
Other: LAKARTIDNINGEN. 2017;114:ELAI
[Rapid improvement of tick-borne encephalitis after treatment with corticosteroids].
Wengse C; Ericsson J; Hallberg S; Ursing J

Doktorand, Kliniska vetenskaper, Danderyds sjukhus, Karolinska Institutet, 2022-2025

Research School for Clinicians in Epidemiology 2019-2021, Epidemiology, KEP, Karolinska Institute, 2019
Läkarexamen, Karolinska Institutet, 2002